Iovance hits highest since 2024 as analysts cheer guidance raise
Iovance Therapeutics shares hit their highest level since 2024 as analysts raised their guidance.
The current stock price of $14.91 significantly exceeds the 20-day resistance level of $11.17, indicating strong upward momentum. Based on the overbought signal with an RSI of 75.7, the bullish alignment of moving averages, and a recent 7-day volatility of +9.7%, a purchase was considered.
If the price breaks above the resistance level at 11.17, take profit at $11.17; if the price falls below the support level at 7.66, cut losses at $7.66.
RSI (14) at 75.7 (overbought), moving averages in a bullish alignment (uptrend), trading volume at 0.89x the 20-day average (volume decreasing), and a +9.7% change over the past 7 days (rising trend).
The historical records of a +28.8% surge on 2026-08-14 and a +12.4% increase on 2026-08-06 showed a pattern of rapid rallies following positive news, raising expectations for a similar upward move upon this guidance hike, but the outcome was different.
The forecast predicted the stock price would continue its upward trend and yield a 4.5% return, but it actually resulted in a -13.1% loss, failing to reach the stop-loss level. The erroneous decision to buy—despite the RSI already being in the overbought zone at 75.7 and trading volume being below average—was caused by overconfidence that the current price, which significantly exceeded the resistance level, was sustainable. On the other hand, the recent 7-day volatility of +9.7% and the bullish alignment of moving averages suggested upside potential, but this was insufficiently verified.
For the next trades, entry should be withheld when the RSI is 70 or above, and a cautious approach should be taken even when trading volume is below average. In addition, take profits when the price rises by a certain percentage (e.g., 5%) after breaking through a resistance line, and limit risk by setting a more conservative stop-loss level. General disclosures such as SEC Form 8-K should be viewed neutrally, and the increasing trend in thematic news should be continuously monitored.